| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1510 | |
| Phytochemical name or plant extracts | Glabridin | |
| PMID | 28464803 | |
| Literature evidence | CONCLUSIONS: Our study identified a molecular mechanism of the GLA inhibition of angiogenesis through the Wnt/β-catenin signaling pathway via miR-148a, suggesting that GLA could serve as an adjuvant chemotherapeutic agent for breast cancer. | |
| IUPAC name | 4-[(3R)-8,8-dimethyl-3,4-dihydro-2H-pyrano[2,3-f]chromen-3-yl]benzene-1,3-diol | |
| Phytochemicals’ class or type of plant extracts | Flavonoid | |
| Source of phytochemicals or plant Extracts | Glycyrrhiza glabra | |
| Geographical availability | Afghanistan, Albania, Bulgaria, Central European Russia, China North-Central, Cyprus, East Aegean Is., East European Russia, Greece, Iran, Iraq, Italy, Kazakhstan, Kirgizstan, Krym, Lebanon-Syria, Mongolia, North Caucasus, Pakistan, Palestine, Romania, Sardegna, Saudi Arabia, Sicilia, South European Russia, Tadzhikistan, Transcaucasus, Turkey, Turkmenistan, Ukraine, Uzbekistan, West Siberia, Xinjiang, Yugoslavia | |
| Plant parts | Root | |
| Other cancers | Breast cancer | |
| Target gene or protein | GLUT1, miR-148a, FAK/Src complex, AKT, ERK1/2 | |
| Gene or Protein evidence | The results showed that both quercetin and glabridin could decrease the glucose uptake capacity of breast cancer cells by down-regulating the protein expression of GLUT1. In MDA-MB-231 and Hs-578T breast cancer cell lines, GLA enhanced the expression of miR-148a through DNA demethylation, in silico target identification analysis revealed that AKT1 are the potential targets for glabridin and their derivatives. Inhibition of the FAK/Src complex by glabridin also blocked AKT and ERK1/2 activation, resulting in reduced activation of RhoA as well as myosin light chain phosphorylation. | |
| Target pathways | Inhibits migration, invasion and angiogenesis of MDA-MB-231 human breast adenocarcinoma cells by inhibiting focal adhesion kinase/Rho signaling pathway, In breast cancer cells, GLA partially inhibited angiogenesis through the Wnt/?-catenin signaling pathway. | |
| IC50 | 58.30 ± 1.15 µM against MCF-7 42.31 ± 1.46 µM against MDA-MB-231 | |
| Potency | Our study identified a molecular mechanism of the GLA inhibition of angiogenesis through the Wnt/?-catenin signaling pathway via miR-148a, suggesting that GLA could serve as an adjuvant chemotherapeutic agent for breast cancer. | |
| Cell line/ mice model | MDA-MB-231, HEK-293, K562, MCF-7, HeLa, HepG2 and WRL-68 | |
| Additional information | Both quercetin and glabridin can regulate the energy metabolism of breast cancer cells and can be used as potential anticancer agents or anti-cancer adjuvants. The combination of 1 x 10(-5)M tamoxifen and 1 x 10(-6)M glabridin exhibited estrogenic activities and suppressed cell growth in both cell lines. | |
| PubChem ID | 124052 | |
| Additional PMIDs | 28464803 25980823 26594762 20626003 30959046 31602954 27539316 30580626 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:496941-1 | |
| Safety | NA |